Provided by Tiger Trade Technology Pte. Ltd.

Immunocore Holdings plc

34.74
+0.56001.64%
Volume:352.96K
Turnover:12.17M
Market Cap:1.79B
PE:-97.42
High:34.87
Open:34.33
Low:34.13
Close:34.18
52wk High:40.71
52wk Low:27.56
Shares:51.50M
Float Shares:42.66M
Volume Ratio:0.81
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3566
EPS(LYR):-0.7054
ROE:-4.47%
ROA:-0.16%
PB:4.26
PE(LYR):-49.25

Loading ...

Immunocore price target raised to $43 from $40 at Morgan Stanley

TIPRANKS
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), Immunocore Holdings (IMCR) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Aug 07

Analysts Are Bullish on These Healthcare Stocks: Immunocore Holdings (IMCR), Natera (NTRA)

TIPRANKS
·
Aug 07

Needham Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)

TIPRANKS
·
Aug 06

Immunocore Holdings PLC Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Immunocore Publishes Corporate Presentation on Bispecific Soluble TCR Platform and Pipeline Across Oncology, Infectious and Autoimmune Diseases

Reuters
·
Aug 06

Earnings Flash (IMCR) Immunocore Posts Q2 Loss $0.02 a Share, vs. FactSet Est of $0.02 Loss

MT Newswires Live
·
Aug 06

UK's Immunocore Q2 EPS Misses Estimates

Reuters
·
Aug 06

Immunocore Q2 FY26 Net Loss Narrows to $0.8 Million; Revenue Rises 18% to $115.9 Million

Reuters
·
Aug 06

Immunocore Hldgs Q2 EPS $(0.02) Misses $0.02 Estimate, Sales $115.927M Beat $110.374M Estimate

Benzinga Earnings
·
Aug 06

Press Release: Immunocore Reports Second Quarter Financial Results and Provides a Business Update

Dow Jones
·
Aug 06

Immunocore Holdings PLC Expected to Post Earnings of 1 Cent a Share - Earnings Preview

Reuters
·
Aug 04

Immunocore to Report Q2 Financial Results, Host Investor Call

Reuters
·
Jul 30

The Bull Case For Immunocore Holdings (IMCR) Could Change Following New Brenetafusp Melanoma Data - Learn Why

Simply Wall St.
·
Jun 11

Immunocore Holdings (IMCR) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Jun 04

What Immunocore Holdings (IMCR)'s Phase 1 Brenetafusp Data and 160 mcg Dose Choice Means For Shareholders

Simply Wall St.
·
Jun 01

Immunocore Reports 14.3-Month Survival in Phase 1/2 Trial of Advanced Melanoma Drug Candidate

MT Newswires Live
·
Jun 01

Immunocore presents updated results from Phase 1/2 trial of brenetafusp

TIPRANKS
·
Jun 01

Immunocore says Phase 1 brenetafusp data show 87% 6-month survival in advanced melanoma patients

Reuters
·
May 31

Immunocore Shareholders Back All Proposals at 2026 AGM

TIPRANKS
·
May 28